t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...

Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.

As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

Dr. Shune highlights that the growing availability of FDA-approved agents with distinct and complementary mechanisms has ...

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

Dr. Shune concludes the discussion by focusing on safety, sequencing, and practical considerations for incorporating ...

Overall, this segment establishes a nuanced view of prognosis that avoids binary categorization. Instead, Dr Shaheen frames ...

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...

Median overall survival differed significantly by race: 36.8 months for Black patients versus 48.4 months for White patients ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, gastrointestinal (GI) medical oncologist at Baptist Health ...